Security
Nektar Therapeutics Common Stock · NKTR
NKTRNASDAQCommon stockCurrentCIK 906709Updated Oct 4, 2026
Name history
INHALE THERAPEUTIC SYSTEMS INC · through Jan 10, 2003INHALE THERAPEUTIC SYSTEMS · through May 14, 1998
NKTR price & chart
Loading TradingView…
NASDAQ:NKTR on TradingView ↗About the company
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory Tcell stimulator being evaluated in atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus. Nektar’s pipeline also includes preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.
In the news
NKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit ↗
NKTR DEADLINE NOTICE: ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTR ↗
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Other Events
Items 8.01
Regulation FD Disclosure
Items 7.01, 9.01
144 filing
144 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 280,406,000Source | 303,850,000Source | 398,033,000Source | 710,600,000Source |
| Property, Plant and Equipment, NetUSD | 2,060,000Source | 3,411,000Source | 18,856,000Source | 32,451,000Source |
| GoodwillUSD | — | — | 0Source | 76,501,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 15,116,000Source | 44,252,000Source | 35,277,000Source | 88,227,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 0Source | 1,205,000Source | 5,981,000Source |
| Inventory, NetUSD | 0Source | 0Source | 16,101,000Source | 19,202,000Source |
| Assets, CurrentUSD | 266,266,000Source | 261,292,000Source | 330,701,000Source | 545,968,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,941,000Source | 8,413,000Source | 18,007,000Source | 53,435,000Source |
| Other Assets, NoncurrentUSD | 5,648,000Source | 4,647,000Source | 4,644,000Source | 2,245,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 190,574,000Source | 243,113,000Source | 267,046,000Source | 343,962,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 2,000Source | 19,000Source | 19,000Source | 19,000Source |
| Retained Earnings (Accumulated Deficit)USD | -3,760,286,000Source | -3,596,210,000Source | -3,477,249,000Source | -3,201,193,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 17,000Source | 61,000Source | 80,000Source | -6,907,000Source |
| Stockholders' Equity Attributable to ParentUSD | 89,832,000Source | 60,737,000Source | 130,987,000Source | 366,638,000Source |
| Additional Paid in Capital, Common StockUSD | 3,850,099,000Source | 3,659,867,000Source | 3,608,137,000Source | 3,574,719,000Source |
| Liabilities and EquityUSD | 280,406,000Source | 303,850,000Source | 398,033,000Source | 710,600,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 53,536,000Source | 61,400,000Source | 51,269,000Source | 68,204,000Source |
| Operating Lease, Liability, CurrentUSD | 20,495,000Source | 19,868,000Source | 19,259,000Source | 18,667,000Source |
| Accounts Payable, CurrentUSD | 10,770,000Source | 11,560,000Source | 9,848,000Source | 12,980,000Source |
| Operating Lease, Liability, NoncurrentUSD | 65,256,000Source | 82,696,000Source | 98,517,000Source | 112,829,000Source |
| Other Liabilities, NoncurrentUSD | 8,625,000Source | 7,241,000Source | 4,635,000Source | 7,551,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 22,271,000Source | 29,972,000Source | 22,162,000Source | — |
| Deferred Tax Liabilities, NetUSD | 575,000Source | 510,000Source | 520,000Source | 2,405,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -164,076,000Source | -118,961,000Source | -276,056,000Source | -368,198,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | 4,100,000Source | 7,000,000Source | 12,200,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 0Source | 3,045,000Source | -4,776,000Source | -16,511,000Source |
| Increase (Decrease) in InventoriesUSD | 0Source | -497,000Source | -699,000Source | 3,401,000Source |
| Increase (Decrease) in Accounts PayableUSD | -625,000Source | 2,668,000Source | -2,884,000Source | 3,103,000Source |
| Deferred Income Tax Expense (Benefit)USD | 64,000Source | -10,000Source | -140,000Source | 2,708,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -208,511,000Source | -175,709,000Source | -192,606,000Source | -304,007,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -1,197,000Source | 142,570,000Source | 139,564,000Source | 365,835,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 171,000Source | 1,468,000Source | 865,000Source | 5,676,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 0Source | 3,000,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 180,566,000Source | 42,118,000Source | 30,000Source | 1,508,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -29,136,000Source | 8,975,000Source | -52,950,000Source | 63,009,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 15,116,000Source | 44,252,000Source | 35,277,000Source | 88,227,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | 0Source |
| Income Taxes Paid, NetUSD | -195,000Source | 76,000Source | 2,656,000Source | 272,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 6,000Source | -4,000Source | 62,000Source | -327,000Source |
| Additional Financial Items | ||||
| AmortizationUSD | — | — | 1,634,000Source | — |
| Share-based Payment Arrangement, ExpenseUSD | 12,649,000Source | 21,612,000Source | 33,388,000Source | 57,320,000Source |
| Deconsolidation, Gain (Loss), AmountUSD | 0Source | 40,390,000Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | 0Source | -5,099,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | 0Source | -1,300,000Source | 3,326,000Source |
| General and Administrative ExpenseUSD | 68,673,000Source | 76,751,000Source | 77,417,000Source | 92,333,000Source |
| GoodwillUSD | — | — | 0Source | 76,501,000Source |
| Goodwill, Impairment LossUSD | — | 0Source | 76,501,000Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | -8,727,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | -138,000Source | -239,000Source | -200,000Source | 3,215,000Source |
| Investment Income, InterestUSD | 10,438,000Source | 14,500,000Source | 19,009,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -164,076,000Source | -118,961,000Source | -276,056,000Source | -368,198,000Source |
| Nonoperating Income (Expense)USD | -15,385,000Source | -14,002,000Source | -12,572,000Source | 11,183,000Source |
| Operating Lease, Impairment LossUSD | — | — | 36,962,000Source | — |
| Other Nonoperating Income (Expense)USD | 361,000Source | -390,000Source | -6,247,000Source | 6,667,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 284,683,000Source | 340,361,000Source | 650,883,000Source | 826,229,000Source |
| Restructuring Costs and Asset Impairment ChargesUSD | 9,331,000Source | 15,670,000Source | 51,958,000Source | 135,930,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 55,232,000Source | 98,427,000Source | 90,122,000Source | 92,055,000Source |
| Cost of RevenueUSD | 0Source | 30,686,000Source | 33,768,000Source | 21,635,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Operating Income (Loss)USD | -140,102,000Source | -105,198,000Source | -263,684,000Source | -376,166,000Source |
| Other Nonoperating Income (Expense)USD | 361,000Source | -390,000Source | -6,247,000Source | 6,667,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -164,214,000Source | -119,200,000Source | -276,256,000Source | -364,983,000Source |
| Income Tax Expense (Benefit)USD | -138,000Source | -239,000Source | -200,000Source | 3,215,000Source |
| Net Income (Loss) Attributable to ParentUSD | -164,076,000Source | -118,961,000Source | -276,056,000Source | -368,198,000Source |
| Earnings Per Share, BasicUSD per share | -9.73Source | -0.58Source | -1.45Source | -1.97Source |
| Earnings Per Share, DilutedUSD per share | -9.73Source | -0.58Source | -1.45Source | -1.97Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 16,870,930Source | 205,661,000Source | 190,001,000Source | 187,138,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 16,870,930Source | 205,661,000Source | 190,001,000Source | 187,138,000Source |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 195,334,000Source | 203,625,000Source | 353,806,000Source | 468,221,000Source |
| Current Income Tax Expense (Benefit)USD | -202,000Source | -229,000Source | -60,000Source | 507,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 1,026,000Source | 4,391,000Source | 7,815,000Source | 13,030,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | 0Source | -5,099,000Source | — |
| General and Administrative ExpenseUSD | 68,673,000Source | 76,751,000Source | 77,417,000Source | 92,333,000Source |
| Goodwill, Impairment LossUSD | — | 0Source | 76,501,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -164,576,000Source | -119,227,000Source | -274,998,000Source | -371,900,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | -8,727,000Source | — | — | — |
| Interest ExpenseUSD | — | — | — | 0Source |
| Investment Income, InterestUSD | 10,438,000Source | 14,500,000Source | 19,009,000Source | — |
| Nonoperating Income (Expense)USD | -15,385,000Source | -14,002,000Source | -12,572,000Source | 11,183,000Source |
| Other Cost and Expense, OperatingUSD | 44,727,000Source | 42,047,000Source | — | — |
| Research and Development ExpenseUSD | 117,330,000Source | 120,908,000Source | 114,162,000Source | 218,323,000Source |
Filing attachments
ea030730601ex99-1.htm · 8-K · 2026-10-01
Exhibit 99.1 New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 Rezpegaldesleukin demonstrated durability and deepening of response through one year of treatment in two dermatological indications, reinforcing the differentiated properties of this novel Treg mechanism In alopecia areata patients, SALT Score ≤20 response maintained in 75% at 4 months off treatment and in 63% at six month…
Read attachment ↗ea030730601ex99-2.htm · 8-K · 2026-10-01
Exhibit 99.2 EADV Analyst and Investor Event October 1, 2026 Forward-Looking Statements 2 Safe Harbor Statement This presentation and any accompanying oral discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Nektar Therapeutics' (the "Company" or "Nektar")'s plans, progress, and timing relating to the Company's rezpegaldesleukin programs in alopecia area…
Read attachment ↗ea030192901ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 ea030192901ex99-1.htm PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS SECOND QUARTER 2026 RESULTS." Exhibit 99.1 Nektar Therapeutics Announces Second Quarter 2026 Financial Results SAN FRANCISCO, Aug 13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today reported financial results for the second quarter ended June 30, 2026. Cash and investments in marketable securities on J…
Read attachment ↗ea028961101ex99-1.htm · 8-K · 2026-05-07
EX-99.1 2 ea028961101ex99-1.htm PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FIRST QUARTER 2026 RESULTS." Exhibit 99.1 Nektar Therapeutics Reports First Quarter 2026 Financial Results SAN FRANCISCO, May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026. Cash and investments in marketable securities on March 31, 2026, were $731.6 million as compared to $245.8 million on December 31, 2025. Nektar’s cas…
Read attachment ↗d80358dex991.htm · 8-K · 2026-04-23
EX-99.1 4 d80358dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering SAN FRANCISCO, April 21, 2026 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten public offering of $325 million of shares of its common stock. Nektar is selling 3,532,609 shares of …
Read attachment ↗d25375dex991.htm · 8-K · 2026-04-20
EX-99.1 2 d25375dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin 29% and 31% of patients in the 18 µg/kg and 24 µg/kg extension arms, respectively, achieved new SALT Score ≤20 from week 36 to week 52 with continued twice-monthly treatment Increasing proportions of patients achieved clinically meaningful hair growth thr…
Read attachment ↗